MedTrace Logo

TRANSFORM-HF Ancillary Mechanistic Study

NCT04702958 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-10-10

No results posted yet for this study

Summary

Patients with heart failure are frequently treated with diuretics, including furosemide and torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is studying if torsemide is superior than furosemide for reducing the endpoint of death or hospitalization, but is not designed to study why. This ancillary study seeks to measure proteins in the blood and urine to help explain the underlying mechanism for why patients who take one of these diuretics may have better outcomes than patients who take the other.

Conditions

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Duke University

    collaborator OTHER

  • George Mason University

    collaborator OTHER

  • University of Maryland, Baltimore

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Lauren Cooper, MD, MHS · Northwell Health

  • Christopher deFilippi, MD · Inova Health Care Services

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2023-05-30
Completion
2023-05-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04702958 on ClinicalTrials.gov